Jul. 30 at 2:03 PM
🧵 1/ The first Q2/H1 2025 earnings from the BIOTECH 🧬 sector are out.
Several European players lead the way, but a few US names are in the mix too.
💡For investors:
Here’s a breakdown of revenue, cash, runway & upcoming clinical milestones. Let’s go 👇
DBV Technologies
$DBVT 🇫🇷
• Q2 revenue:
$1.47M
• Cash:
$103.2M (up from
$32.5M in 2024)
• Net loss Q2: –
$41.9M
• Higher R&D spend driven by COMFORT Toddlers trial
Inventiva
$IVA 🇫🇷
• H1 revenue: €4.5M (vs €0M in 2024)
• H1 OpEx: €53.9M. R&D flat at €45.2M
• Cash: €122M – runway into Q3 2026
📌 Preparing for key milestones but will need additional funding
Idorsia
$IDIA 🇨🇭
• H1 revenue: CHF 131M
• Cash runway: into end‑2026
• QUVIVIQ (insomnia) drives sales: +145% YoY
🔜 Approaching profitability by late 2027
Galapagos
$GLPG 🇧🇪
• H1 revenue: €140M (flat YoY)
• H1 net loss: –€259M
• Cash: €3.09B
🔁 Major restructuring underway:
Innovative unit spin-off & 40% workforce cut
